ALK expects to have approved peanut allergy vaccine in 2030
After revealing that it is starting a phase I trial of its peanut allergy vaccine candidate, ALK has now announced that it expects to have an approved vaccine in 2030 at the latest.
by marketwire, translated by catherine brett
Head of R&D at ALK Henrik Jacobi thinks the decision to move into peanut allergies makes sense, as the firm already has a lot of experience of developing tablet-based vaccines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK to start phase I trial of peanut allergy tablet vaccine
For subscribers
ALK finds replacement for long-time North America lead
For subscribers
.jpg)
.jpg&w=384&q=75)
